vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $196.0M, roughly 1.7× Axsome Therapeutics, Inc.). PRA GROUP INC runs the higher net margin — 17.0% vs -14.6%, a 31.5% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 13.7%). Axsome Therapeutics, Inc. produced more free cash flow last quarter ($-18.7M vs $-90.4M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 14.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
AXSM vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $333.4M |
| Net Profit | $-28.6M | $56.5M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 37.7% |
| Net Margin | -14.6% | 17.0% |
| Revenue YoY | 65.0% | 13.7% |
| Net Profit YoY | 61.9% | 206.3% |
| EPS (diluted) | $-0.55 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $333.4M | ||
| Q3 25 | $171.0M | $311.1M | ||
| Q2 25 | $150.0M | $287.7M | ||
| Q1 25 | $121.5M | $269.6M | ||
| Q4 24 | $118.8M | $293.2M | ||
| Q3 24 | $104.8M | $281.5M | ||
| Q2 24 | $87.2M | $284.2M | ||
| Q1 24 | $75.0M | $255.6M |
| Q4 25 | $-28.6M | $56.5M | ||
| Q3 25 | $-47.2M | $-407.7M | ||
| Q2 25 | $-48.0M | $42.4M | ||
| Q1 25 | $-59.4M | $3.7M | ||
| Q4 24 | $-74.9M | $18.5M | ||
| Q3 24 | $-64.6M | $27.2M | ||
| Q2 24 | $-79.3M | $21.5M | ||
| Q1 24 | $-68.4M | $3.5M |
| Q4 25 | -13.8% | 37.7% | ||
| Q3 25 | -27.0% | -101.4% | ||
| Q2 25 | -24.5% | 29.6% | ||
| Q1 25 | -46.9% | 27.7% | ||
| Q4 24 | -61.1% | 32.1% | ||
| Q3 24 | -59.8% | 32.0% | ||
| Q2 24 | -89.5% | 31.4% | ||
| Q1 24 | -89.7% | 26.0% |
| Q4 25 | -14.6% | 17.0% | ||
| Q3 25 | -27.6% | -131.0% | ||
| Q2 25 | -32.0% | 14.7% | ||
| Q1 25 | -48.9% | 1.4% | ||
| Q4 24 | -63.1% | 6.3% | ||
| Q3 24 | -61.7% | 9.6% | ||
| Q2 24 | -91.0% | 7.6% | ||
| Q1 24 | -91.1% | 1.4% |
| Q4 25 | $-0.55 | $1.47 | ||
| Q3 25 | $-0.94 | $-10.43 | ||
| Q2 25 | $-0.97 | $1.08 | ||
| Q1 25 | $-1.22 | $0.09 | ||
| Q4 24 | $-1.54 | $0.47 | ||
| Q3 24 | $-1.34 | $0.69 | ||
| Q2 24 | $-1.67 | $0.54 | ||
| Q1 24 | $-1.44 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $104.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $979.9M |
| Total Assets | $689.8M | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $104.4M | ||
| Q3 25 | $325.3M | $107.5M | ||
| Q2 25 | $303.0M | $131.6M | ||
| Q1 25 | $300.9M | $128.7M | ||
| Q4 24 | $315.4M | $105.9M | ||
| Q3 24 | $327.3M | $141.1M | ||
| Q2 24 | $315.7M | $118.9M | ||
| Q1 24 | $331.4M | $108.1M |
| Q4 25 | $88.3M | $979.9M | ||
| Q3 25 | $73.7M | $928.5M | ||
| Q2 25 | $73.1M | $1.3B | ||
| Q1 25 | $53.2M | $1.2B | ||
| Q4 24 | $57.0M | $1.1B | ||
| Q3 24 | $92.9M | $1.2B | ||
| Q2 24 | $102.9M | $1.1B | ||
| Q1 24 | $144.0M | $1.1B |
| Q4 25 | $689.8M | $5.1B | ||
| Q3 25 | $669.3M | $5.0B | ||
| Q2 25 | $639.8M | $5.4B | ||
| Q1 25 | $596.7M | $5.1B | ||
| Q4 24 | $568.5M | $4.9B | ||
| Q3 24 | $561.5M | $4.9B | ||
| Q2 24 | $548.2M | $4.7B | ||
| Q1 24 | $545.7M | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $-85.5M |
| Free Cash FlowOCF − Capex | $-18.7M | $-90.4M |
| FCF MarginFCF / Revenue | -9.6% | -27.1% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $-85.5M | ||
| Q3 25 | $1.0M | $-10.1M | ||
| Q2 25 | $-32.4M | $-12.9M | ||
| Q1 25 | $-43.4M | $-52.6M | ||
| Q4 24 | $-26.2M | $-94.6M | ||
| Q3 24 | $-18.6M | $-35.0M | ||
| Q2 24 | $-30.1M | $-29.5M | ||
| Q1 24 | $-53.5M | $-73.0M |
| Q4 25 | $-18.7M | $-90.4M | ||
| Q3 25 | $988.0K | $-11.3M | ||
| Q2 25 | $-32.4M | $-14.2M | ||
| Q1 25 | $-43.7M | $-53.5M | ||
| Q4 24 | $-26.2M | $-98.6M | ||
| Q3 24 | $-18.7M | $-36.1M | ||
| Q2 24 | $-30.2M | $-30.8M | ||
| Q1 24 | $-53.6M | $-73.5M |
| Q4 25 | -9.6% | -27.1% | ||
| Q3 25 | 0.6% | -3.6% | ||
| Q2 25 | -21.6% | -4.9% | ||
| Q1 25 | -36.0% | -19.8% | ||
| Q4 24 | -22.1% | -33.6% | ||
| Q3 24 | -17.9% | -12.8% | ||
| Q2 24 | -34.6% | -10.8% | ||
| Q1 24 | -71.4% | -28.8% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.3% | 0.3% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 0.1% | 0.4% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.1% | 0.2% |
| Q4 25 | — | -1.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.30× | ||
| Q1 25 | — | -14.37× | ||
| Q4 24 | — | -5.13× | ||
| Q3 24 | — | -1.29× | ||
| Q2 24 | — | -1.37× | ||
| Q1 24 | — | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
